Baxter International Inc. (BAX)
NYSE: BAX · Real-Time Price · USD
22.04
+0.49 (2.27%)
At close: Jun 26, 2026, 4:00 PM EDT
22.05
+0.01 (0.05%)
After-hours: Jun 26, 2026, 7:50 PM EDT
Revenue Breakdown
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 |
Infusion Therapies Revenue | 4.09B | 4.10B | 4.10B | ||||||||||||
Infusion Therapies Revenue Growth | -0.32% | -0.05% | 3.61% | ||||||||||||
Advanced Surgery Revenue | 1.23B | 1.20B | 1.10B | ||||||||||||
Advanced Surgery Revenue Growth | 3.00% | 8.51% | 5.04% | ||||||||||||
Medical Products & Therapies Revenue | 5.32B | 5.30B | 5.21B | ||||||||||||
Medical Products & Therapies Revenue Growth | 0.43% | 1.77% | 3.91% | ||||||||||||
Care & Connectivity Solutions Revenue | 1.92B | 1.91B | 1.81B | ||||||||||||
Care & Connectivity Solutions Revenue Growth | 0.42% | 5.35% | 0.78% | ||||||||||||
Front Line Care Revenue | 1.15B | 1.16B | 1.14B | ||||||||||||
Front Line Care Revenue Growth | -0.60% | 2.02% | -6.26% | ||||||||||||
Healthcare Systems & Technologies Revenue | 3.07B | 3.07B | 2.95B | ||||||||||||
Healthcare Systems & Technologies Revenue Growth | 0.03% | 4.07% | -2.06% | ||||||||||||
Injectables and Anesthesia Revenue | 1.32B | 1.35B | 1.37B | ||||||||||||
Injectables and Anesthesia Revenue Growth | -2.51% | -1.53% | 1.93% | ||||||||||||
Drug Compounding Revenue | 1.22B | 1.14B | 1.04B | ||||||||||||
Drug Compounding Revenue Growth | 6.49% | 9.92% | 15.08% | ||||||||||||
Pharmaceuticals Revenue | 2.53B | 2.49B | 2.41B | ||||||||||||
Pharmaceuticals Revenue Growth | 1.60% | 3.40% | 7.20% | ||||||||||||
Other Revenue (Post-Q2 2023 Reporting) | 393.00M | 381.00M | 67.00M | ||||||||||||
Other Revenue (Post-Q2 2023 Reporting) Growth | 3.15% | 468.66% | -22.99% | ||||||||||||
Revenue (Total) | 11.32B | 11.24B | 10.64B | ||||||||||||
Revenue (Total) Growth | 0.68% | 5.72% | 2.66% |
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 |
United States Revenue | 6.07B | 6.12B | 5.85B | ||||||||||||
United States Revenue Growth | -0.90% | 4.65% | 0.83% | ||||||||||||
Emerging Markets Revenue | - | 1.39B | 1.35B | ||||||||||||
Emerging Markets Revenue Growth | - | 3.26% | 0.52% | ||||||||||||
Rest of World Revenue | - | 3.73B | 3.44B | ||||||||||||
Rest of World Revenue Growth | - | 8.50% | 6.87% | ||||||||||||
International Revenue | 5.25B | 5.12B | 4.79B | ||||||||||||
International Revenue Growth | 2.56% | 7.02% | 5.00% | ||||||||||||
Revenue (Other) | - | -5.12B | -4.79B | ||||||||||||
Revenue (Total) | 11.32B | 11.24B | 10.64B | ||||||||||||
Revenue (Total) Growth | 0.68% | 5.72% | 2.66% |
EBIT
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 |
Medical Products & Therapies Operating Income | 912.00M | 970.00M | 950.00M | ||||||||||||
Medical Products & Therapies Operating Income Growth | -5.98% | 2.10% | -2.26% | ||||||||||||
Healthcare Systems & Technologies Operating Income | 414.00M | 441.00M | 468.00M | ||||||||||||
Healthcare Systems & Technologies Operating Income Growth | -6.12% | -5.77% | -3.11% | ||||||||||||
Pharmaceuticals Operating Income | 205.00M | 222.00M | 313.00M | ||||||||||||
Pharmaceuticals Operating Income Growth | -7.66% | -29.07% | -21.95% | ||||||||||||
Other Operating Income | 45.00M | 43.00M | 18.00M | ||||||||||||
Other Operating Income Growth | 4.65% | 138.89% | - | ||||||||||||
Operating Income (Total) | -300.00M | -308.00M | 14.00M | ||||||||||||
Operating Income (Total) Growth | - | - | -98.02% |